marked.bio

BRAF dimer breaker · small molecule

plixorafenib

2 active trials, targeting BRAF. Not approved for any biomarker on marked.bio yet.

Also known as PLX8394, FORE8394.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 2 2 Phase 2

Sponsors

Industry sponsors leading active biomarker-selected trials of plixorafenib.

  1. Fore Biotherapeutics 1

Trials

2 of 2 trials shown

  1. A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations

    Recruiting Phase 2 Fore Biotherapeutics Started 2023Primary completion 2027-12 NCT05503797

    plixorafenib

    Documented BRAF V600E mutation in tumor and/or liquid biopsy detected by an analytically validated test at CLIA…

    BRAF V600ECancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors

  2. A Trial to Evaluate CSF ctDNA and Safety of Plixorafenib Alone or With Retifanlimab in Patients With BRAF-altered Glioma

    Recruiting Early Phase 1 Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Started 2025Primary completion 2027-06 NCT06610682

    plixorafenibretifanlimab

    Histologic diagnosis of a primary CNS tumor with documented BRAF-V600E mutation by a CLIA approved DNA or RNA-based sequencing test (NGS or RNAseq).

    BRAF V600EBRAF V600E Mutation